Telix QSAM Inc (QSAM)

[RandyKCMO]

An Example I’d what I’m talking about.

News Release Today: QSAM Biosciences Seeks to Expand Radiochemical Assets; Signs Option Agreement to License its Second Promising Cancer Therapy

Austin, Texas, March 17, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM) announced today that it has signed an Exclusive Option Agreement with IsoTherapeutics Group, LLC to allow the Company a 120-day period to perform diligence and negotiate a worldwide, exclusive license agreement for a pre-clinical staged radiochemical therapy called BetaBrach™.

BetaBrach is a brachytherapy, a cancer treatment where radioactive implants are inserted directly into diseased tissue to eradicate the target tumor. BetaBrach uses beta radiation (Yyttrium-90) chemically formulated to significantly reduce migration to non-targeted healthy tissue. It has been used extensively in numerous small animal laboratory models of cancer as well as in the University of Missouri’s College of Veterinary Medicine to treat large animals with naturally occurring tumors with very promising results. Such therapy could be used to treat many types of cancer in humans, including breast and prostate.

“This is an important step in our strategy to build a pipeline of radiochemical assets to develop and commercialize for critical and high unmet medical needs, such as cancer,” stated Douglas R. Baum, the Company’s CEO and Co-Founder. “Delivering a precise and personalized dose of BetaBrach directly to the targeted tumor has the potential to be an optimal treatment option for a broad base of cancer patients, as we believe it can also prevent the debilitating side effects and systemic toxicity associated with current treatments such as chemotherapy.”

The option to license BetaBrach follows the Company’s strategy used to acquire the worldwide rights to CycloSam® (Samarium-153 DOTMP) in 2020 from an IsoTherapeutics affiliated company whose founders created Quadramet® (Samarium-153-EDTMP), one of the first FDA approved and commercially available radiopharmaceuticals.






https://www.otcmarkets.com/stock/QSAM/news/QSAM-Biosciences-Seeks-to-Expand-Radiochemical-Assets-Signs-Option-Agreement-to-License-its-Second-Promising-Cancer-Ther?id=294067